• 1
    Eckel RH, Barouch WW, Ershow AG. Report of the National Heart, Lung, and Blood Institute-National Institute of Diabetes and Digestive and Kidney Diseases Working Group on the pathophysiology of obesity-associated cardiovascular disease. Circulation 2002;105:29232928.
  • 2
    Sowers JR. Obesity as a cardiovascular risk factor. Am J Med 2003;115 Suppl 8A:37S41S.
  • 3
    Ren J. Leptin and hyperleptinemia — from friend to foe for cardiovascular function. J Endocrinol 2004;181:110.
  • 4
    Nair RP, Ren J. Pharmacotherapy of obesity — benefit, bias and hyperbole. Curr Med Chem 2009;16:18881897.
  • 5
    Misra A, Singhal N, Khurana L. Obesity, the metabolic syndrome, and type 2 diabetes in developing countries: role of dietary fats and oils. J Am Coll Nutr 2010;29:289S301S.
  • 6
    Stryjecki C, Mutch DM. Fatty acid-gene interactions, adipokines and obesity. Eur J Clin Nutr 2011;65:285297.
  • 7
    Fernández-Veledo S, Nieto-Vazquez I, Vila-Bedmar R et al. Molecular mechanisms involved in obesity-associated insulin resistance: therapeutical approach. Arch Physiol Biochem 2009;115:227239.
  • 8
    Sutherland JP, McKinley B, Eckel RH. The metabolic syndrome and inflammation. Metab Syndr Relat Disord 2004;2:82104.
  • 9
    Norris DA, Travers JB, Leung DY. Lymphocyte activation in the pathogenesis of psoriasis. J Invest Dermatol 1997;109:14.
  • 10
    Lecube A, Sampol G, Muñoz X et al. TNF-a system and lung function impairment in obesity. Cytokine 2011;54:121124.
  • 11
    Pyrzak B, Wisniewska A, Popko K, Demkow U, Kucharska AM. Association between anthropometric measures of obesity, metabolic disturbances and polymorphism G-308A of the tumor necrosis factor-alpha gene in children. Eur J Med Res 2010;15 Suppl 2:141146.
  • 12
    Yen GC, Chen YC, Chang WT, Hsu CL. Effects of polyphenolic compounds on tumor necrosis factor-a (TNF-a)-induced changes of adipokines and oxidative stress in 3T3-L1 adipocytes. J Agric Food Chem 2011;59:546551.
  • 13
    Chaulet C, Croix C, Alagille D et al. Design, synthesis and biological evaluation of new thalidomide analogues as TNF-a and IL-6 production inhibitors. Bioorg Med Chem Lett 2011;21:10191022.
  • 14
    De Sanctis JB, Mijares M, Suárez A et al. Pharmacological properties of thalidomide and its analogues. Recent Pat Inflamm Allergy Drug Discov 2010;4:144148.
  • 15
    Kim Y, Alpmann P, Blaum-Feder S et al. Increased in vivo efficacy of lenalidomide by addition of piroctone olamine. In Vivo 2011;25:99103.
  • 16
    Kumar G, Lau H, Laskin O. Lenalidomide: in vitro evaluation of the metabolism and assessment of cytochrome P450 inhibition and induction. Cancer Chemother Pharmacol 2009;63:11711175.
  • 17
    Gordon JN, Prothero JD, Thornton CA et al. CC-10004 but not thalidomide or lenalidomide inhibits lamina propria mononuclear cell TNF-a and MMP-3 production in patients with inflammatory bowel disease. J Crohns Colitis 2009;3:175182.
  • 18
    Kiaei M, Petri S, Kipiani K et al. Thalidomide and lenalidomide extend survival in a transgenic mouse model of amyotrophic lateral sclerosis. J Neurosci 2006;26:24672473.
  • 19
    Reddy N, Hernandez-Ilizaliturri FJ, Deeb G et al. Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo. Br J Haematol 2008;140:3645.
  • 20
    Ren J, Dong F, Cai GJ et al. Interaction between age and obesity on cardiomyocyte contractile function: role of leptin and stress signaling. PLoS One. 2010;5:e10085.
  • 21
    Kushiro K, Núñez NP. Ob/ob serum promotes a mesenchymal cell phenotype in B16BL6 melanoma cells. Clin Exp Metastasis 2011;28: 877886.
  • 22
    Ceylan-Isik AF, Sreejayan N, Ren J. Endoplasmic reticulum chaperon tauroursodeoxycholic acid alleviates obesity-induced myocardial contractile dysfunction. J Mol Cell Cardiol 2011;50:107116.
  • 23
    Dong F, Zhang X, Culver B et al. Dietary iron deficiency induces ventricular dilation, mitochondrial ultrastructural aberrations and cytochrome c release: involvement of nitric oxide synthase and protein tyrosine nitration. Clin Sci (Lond) 2005;109:277286.
  • 24
    Kantari C, Walczak H. Caspase-8 and bid: caught in the act between death receptors and mitochondria. Biochim Biophys Acta 2011;1813:558563.
  • 25
    Morris DL, Rui L. Recent advances in understanding leptin signaling and leptin resistance. Am J Physiol Endocrinol Metab 2009;297:E1247E1259.
  • 26
    Dong F, Fang CX, Yang X et al. Cardiac overexpression of catalase rescues cardiac contractile dysfunction induced by insulin resistance: Role of oxidative stress, protein carbonyl formation and insulin sensitivity. Diabetologia 2006;49:14211433.
  • 27
    Li SY, Yang X, Ceylan-Isik AF et al. Cardiac contractile dysfunction in Lep/Lep obesity is accompanied by NADPH oxidase activation, oxidative modification of sarco(endo)plasmic reticulum Ca2+-ATPase and myosin heavy chain isozyme switch. Diabetologia 2006;49:14341446.
  • 28
    Fang CX, Dong F, Thomas DP et al. Hypertrophic cardiomyopathy in high-fat diet-induced obesity: role of suppression of forkhead transcription factor and atrophy gene transcription. Am J Physiol Heart Circ Physiol 2008;295:H1206H1215.
  • 29
    Park JH, Song YM, Sung J et al. The association between fat and lean mass and bone mineral density: the Healthy Twin Study. Bone 2012;50:10061011.
  • 30
    Scheller EL, Song J, Dishowitz MI, Hankenson KD, Krebsbach PH. A potential role for the myeloid lineage in leptin-regulated bone metabolism. Horm Metab Res 2012;44:15.
  • 31
    Manago S, Yonehara S. [TNF family (TNF alpha, beta, FasL, CD40L)]. Nippon Rinsho 2005;63 Suppl 4:202206.
  • 32
    Chen Z, Leskinen H, Liimatta E et al. Myocardial overexpression of Mecr, a gene of mitochondrial FAS II leads to cardiac dysfunction in mouse. PLoS One. 2009;4:e5589.
  • 33
    Randhawa SR, Chahine BG, Lowery-Nordberg M, Cotelingam JD, Casillas AM. Underexpression and overexpression of Fas and Fas ligand: a double-edged sword. Ann Allergy Asthma Immunol 2010;104:286292.
  • 34
    Wesche-Soldato DE, Swan RZ, Chung CS, Ayala A. The apoptotic pathway as a therapeutic target in sepsis. Curr Drug Targets 2007;8:493500.
  • 35
    Tafani M, Karpinich NO, Hurster KA et al. Cytochrome c release upon Fas receptor activation depends on translocation of full-length bid and the induction of the mitochondrial permeability transition. J Biol Chem 2002;277:1007310082.
  • 36
    Feng X, Yan J, Wang Y et al. The proteasome inhibitor bortezomib disrupts tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression and natural killer (NK) cell killing of TRAIL receptor-positive multiple myeloma cells. Mol Immunol 2010;47:23882396.
  • 37
    Ren J, Pulakat L, Whaley-Connell A, Sowers JR. Mitochondrial biogenesis in the metabolic syndrome and cardiovascular disease. J Mol Med 2010;88:9931001.
  • 38
    Tanti JF, Jager J. Cellular mechanisms of insulin resistance: role of stress-regulated serine kinases and insulin receptor substrates (IRS) serine phosphorylation. Curr Opin Pharmacol 2009;9:753762.
  • 39
    Sun Y, Liu G, Song T et al. Upregulation of GRP78 and caspase-12 in diastolic failing heart. Acta Biochim Pol 2008;55:511516.
  • 40
    Groenendyk J, Sreenivasaiah PK, Kim H, Agellon LB, Michalak M. Biology of endoplasmic reticulum stress in the heart. Circ Res 2010;107:11851197.